Floatz logo

m3814

Locally Advanced Unresectable Cholangiocarcinoma

National Cancer Institute (NCI)Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Locally Advanced Unresectable Cholangiocarcinoma cohort.

Asset / SponsorPhaseRating
Avelumab
National Cancer Institute (NCI)
Phase 1/2CC

Same molecule, other indications

m3814 is also rated in:

Advanced Solid TumorsDormant
CCC
Indicative ·
52 / 100
View asset →
Unresectable Malignant Solid NeoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
Locally Advanced Unresectable Gallbladder CarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →